Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Raziel & Fosun Start Phase 3 Trial in China for Submental Fat Reduction Treatment
Details : RZL-012 is an injectable lipolytic drug, works by destroys fat cells and reduces fat volume, currently being developed for the reduction of unwanted submental fat in adults
Product Name : RZL-012
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2025
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZL 012
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Fosun Pharmaceutical
Deal Size : $74.0 million
Deal Type : Licensing Agreement
Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012
Details : RZL-012 is an injectable drug product indicated for aesthetic treatment of adults having moderate to significant submental fullness. Under the terms of the agreement, Raziel Therapeutics will receive potential payments between now and marketing approval ...
Product Name : RZL 012
Product Type : Other Small Molecule
Upfront Cash : $27.0 million
September 17, 2020
Lead Product(s) : RZL 012
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Fosun Pharmaceutical
Deal Size : $74.0 million
Deal Type : Licensing Agreement
Reset All
